CIRM Funded Clinical Trials

Autologous BCMA CAR-T Cells for the Treatment of Relapsed Refractory Light Chain Amyloidosis

Disease Area:

Blood Disorders

Investigator:

Ilya Rachman MD PhD

Institution:

CIRM Grant:

CLIN2-15901 (Pre-Active)

Award Value:

$7,999,467.00

Trial Sponsor:

Nexcella, Inc.

Trial Stage:

Phase 1

Trial Status:

Launching

Targeted Enrollment:

N/A